ArticleFrontiers in oncology2025
Exploring 2D and 3D radiomic models for predicting microvascular invasion in hepatocellular carcinoma: a novel perspective on tumor heterogeneity.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and validation of a Random Forest prediction model integrating clinical and ultrasound radiomics features for microvascular invasion in hepatocellular carcinoma patients: a retrospective study.Translational cancer research · 2026Article
- A multimodal prediction framework for colorectal cancer peritoneal metastasis: CT-based tumor and adipose tissue analysis.Abdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to develop models for predicting microvascular invasion (MVI) in hepatocellular carcinoma (HCC) patients prior to surgery using two-dimensional (2D) and three-dimensional (3D) radiomics features from contrast-enhanced computed tomography (CT). The study compares the predictive performance of various models and explores the potential of radiomics to capture tumor spatial heterogeneity. Materials and methods: A total of 150 hepatocellular carcinoma (HCC) patients who underwent contrast-enhanced CT examination and curative resection were included in this study. 2D features from the largest cross-sectional slice, as well as 3D radiomic features, were extracted from the non-contrast (NC), arterial phase (AP), portal venous phase (PVP), and balanced phase (BP) images. Feature selection was performed using the least absolute shrinkage and selection operator (LASSO) algorithm, and predictive models were constructed using logistic regression and XGBoost machine learning algorithms. The predictive performance of the models was evaluated using the area under the receiver operating characteristic curve (AUC). Results: The 2D BP model (AUC = 0.801) and 3D PVP model (AUC = 0.876) showed superior performance among single-sequence models. The 2D multi-sequence model (AUC = 0.851) outperformed the 3D combined model (AUC = 0.811). Radiomics-based models outperformed clinical feature-based models, and combining radiomics scores with clinical features improved prediction accuracy. However, 3D models did not significantly outperform 2D models. Conclusion: Both 2D and 3D radiomics models are effective for predicting MVI in HCC patients preoperatively. While the 3D model captures spatial heterogeneity, the 2D model excels at capturing local texture features. This study provides new insights into radiomics in HCC, contributing to its clinical application and standardization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.